The Functional Properties and Physiological Roles of Signal-Transducing Adaptor Protein-2 in the Pathogenesis of Inflammatory and Immune Disorders.

T cell antigen receptor (TCR) T cells immune response signal transduction signal-transducing adaptor protein-2 (STAP-2)

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
30 Nov 2022
Historique:
received: 05 11 2022
revised: 24 11 2022
accepted: 26 11 2022
entrez: 23 12 2022
pubmed: 24 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

Adaptor molecules play a crucial role in signal transduction in immune cells. Several adaptor molecules, such as the linker for the activation of T cells (LAT) and SH2 domain-containing leukocyte protein of 76 kDa (SLP-76), are essential for T cell development and activation following T cell receptor (TCR) aggregation, suggesting that adaptor molecules are good therapeutic targets for T cell-mediated immune disorders, such as autoimmune diseases and allergies. Signal-transducing adaptor protein (STAP)-2 is a member of the STAP family of adaptor proteins. STAP-2 functions as a scaffold for various intracellular proteins, including BRK, signal transducer, and activator of transcription (STAT)3, STAT5, and myeloid differentiation primary response protein (MyD88). In T cells, STAP-2 is involved in stromal cell-derived factor (SDF)-1α-induced migration, integrin-dependent cell adhesion, and Fas-mediated apoptosis. We previously reported the critical function of STAP-2 in TCR-mediated T cell activation and T cell-mediated autoimmune diseases. Here, we review how STAP-2 affects the pathogenesis of T cell-mediated inflammation and immune diseases in order to develop novel STAP-2-targeting therapeutic strategies.

Identifiants

pubmed: 36551835
pii: biomedicines10123079
doi: 10.3390/biomedicines10123079
pmc: PMC9776019
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 19H03364
Organisme : Japan Society for the Promotion of Science
ID : 21K08451

Références

J Immunol. 2012 Jun 15;188(12):6194-204
pubmed: 22611243
Int Immunol. 1999 Jun;11(6):943-50
pubmed: 10360968
Cancer Sci. 2011 Apr;102(4):756-61
pubmed: 21205088
Biochem Biophys Res Commun. 2021 Jun 4;556:185-191
pubmed: 33845308
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11976-81
pubmed: 10518561
Cold Spring Harb Perspect Biol. 2010 Jul;2(7):a002287
pubmed: 20519342
J Immunol. 2007 Mar 15;178(6):3786-96
pubmed: 17339477
J Immunol. 2007 Aug 15;179(4):2397-407
pubmed: 17675501
Nat Rev Immunol. 2010 Sep;10(9):645-56
pubmed: 20725108
Mol Cell Biol. 2003 Apr;23(7):2515-29
pubmed: 12640133
Biochem Biophys Res Commun. 2000 Feb 24;268(3):697-703
pubmed: 10679268
Sci STKE. 2000 Dec 19;2000(63):re1
pubmed: 11752630
J Biol Chem. 2005 Mar 4;280(9):8188-96
pubmed: 15611091
Signal Transduct Target Ther. 2021 Dec 13;6(1):412
pubmed: 34897277
Oncogene. 2020 Aug;39(34):5601-5615
pubmed: 32661325
J Clin Cell Immunol. 2012 Oct 27;2012(Suppl 12):5
pubmed: 23946894
Oncogene. 2000 Aug 31;19(37):4273-82
pubmed: 10980601
Annu Rev Immunol. 2003;21:335-76
pubmed: 12524386
Nat Immunol. 2005 Nov;6(11):1133-41
pubmed: 16200068
Proc Natl Acad Sci U S A. 1988 Nov;85(22):8613-7
pubmed: 3263650
Nat Rev Immunol. 2018 Aug;18(8):485-497
pubmed: 29789755
J Immunol. 2022 Jul 1;209(1):57-68
pubmed: 35725273
Biochem Biophys Res Commun. 2007 Jul 6;358(3):931-7
pubmed: 17512498
Biochem Biophys Res Commun. 2009 Jun 19;384(1):71-5
pubmed: 19393627
J Biol Chem. 2001 Nov 30;276(48):45175-83
pubmed: 11572860
J Biol Chem. 2003 Mar 28;278(13):11182-9
pubmed: 12540842
Sci Signal. 2011 Dec 06;4(202):ra85
pubmed: 22155789
Oncotarget. 2017 May 9;8(19):30766-30780
pubmed: 28430604
Nat Rev Immunol. 2011 Jan;11(1):47-55
pubmed: 21127503
J Immunol. 2002 Sep 15;169(6):2823-7
pubmed: 12218091
J Biol Chem. 1997 Oct 3;272(40):25401-8
pubmed: 9312162
Science. 1998 Jul 17;281(5375):413-6
pubmed: 9665884
Immunity. 1999 Mar;10(3):323-32
pubmed: 10204488
Biol Pharm Bull. 2021;44(7):895-901
pubmed: 34193686
Exp Mol Med. 2020 May;52(5):750-761
pubmed: 32439954
Biol Pharm Bull. 2008 Sep;31(9):1790-3
pubmed: 18758078
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Cell. 1998 Jul 24;94(2):229-38
pubmed: 9695951
Biochem Biophys Res Commun. 2007 May 4;356(2):517-22
pubmed: 17368569
J Immunol. 2006 Jan 1;176(1):380-9
pubmed: 16365431
J Biol Chem. 2017 Nov 24;292(47):19392-19399
pubmed: 28986450
J Immunol. 2009 Dec 15;183(12):7966-74
pubmed: 19933863
Biochem Biophys Res Commun. 2017 Jun 17;488(1):81-87
pubmed: 28478037
Oncogene. 2001 Oct 1;20(44):6284-90
pubmed: 11607830
Blood. 2002 Mar 1;99(5):1866-9
pubmed: 11861309
Nat Immunol. 2018 Jul;19(7):733-741
pubmed: 29915297
Biochem Biophys Res Commun. 2001 Nov 30;289(2):414-20
pubmed: 11716489
Oncogene. 2012 Oct 4;31(40):4384-96
pubmed: 22231445

Auteurs

Jun-Ichi Kashiwakura (JI)

Department of Life Science, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo 0068585, Hokkaido, Japan.

Kenji Oritani (K)

Department of Hematology, International University of Health and Welfare, Narita 2868686, Chiba, Japan.

Tadashi Matsuda (T)

Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 0600812, Hokkaido, Japan.

Classifications MeSH